

Minimally invasive and convenient

All you need is a blood test, a routine and familiar procedure.

No special preparation

ColoSTAT® doesn't need you to change your diet, medication or bowel habits before the test.

More hygienic

Perfect if you prefer not to handle a stool sample.

Improved assessment

ColoSTAT® may identify whether your symptoms indicate a higher risk of colorectal cancer.

Early detection

Colorectal cancers detected early have a 5-year survival rate of more than 90%. This means ColoSTAT® may potentially save your life.¹

References

1. Cancer Australia. Relative survival by stage at diagnosis (colorectal cancer). National Cancer Control Indicators. Published November 5, 2018. <https://ncci.cancer australia.gov.au/outcomes/relative-survival-rate/relative-survival-stage-diagnosis-colorectal-cancer>
2. Bowel Cancer Australia. Bowel Cancer Prognosis. Bowel Cancer Australia. Published November 26, 2024. <https://www.bowelcancer australia.org/diagnosis-treatment/prognosis/>
3. Cancer Australia. Bowel Cancer (Colorectal Cancer) in Australia Statistics. Cancer Australia. Published July 17, 2025. <https://www.cancer australia.gov.au/cancer-types/bowel-cancer/bowel-cancer-colorectal-cancer-australia-statistics>
4. Internal Data, Rhythm Biosciences, 2025

AU-PAT-COLOSTAT-I-2



Speak to your doctor or clinician first to see if ColoSTAT® is right for you. Collection facilities are available at colostat.com.

Simple blood test for the detection of colorectal cancers, based on Australian clinical research.

Rhythm Biosciences is an Australian diagnostics company focused on developing simple, affordable and accurate tests for the early detection of cancers.

Rhythm Biosciences developed ColoSTAT® from innovative CSIRO research.

ColoSTAT® improves the pathway for diagnosing colorectal cancers, and may help reduce morbidity and mortality rates.

ColoSTAT® has been validated across multiple populations, with data supporting its ability to detect early-stage colorectal cancers with high accuracy.

ColoSTAT® makes bowel cancer testing simpler.

COLOSTAT®
Colorectal Cancer Test



ColoSTAT is a blood-based *in-vitro* diagnostic aid used for the triage of colorectal cancer (CRC). It is not diagnostic and needs professional interpretation.

This flyer is for information purposes only. Please ask your doctor if this is appropriate for you.

COLOSTAT®
Colorectal Cancer Test

COLOSTAT[®]

Colorectal Cancer Test

Be diagnosed quickly

ColoSTAT[®] helps your doctor decide whether you need a colonoscopy.

This brand new blood-based test helps detect colorectal cancer.

- ✓ Minimally invasive
- ✓ Fast results in days
- ✓ Clinically safe
- ✓ No stool samples
- ✓ No unnecessary colonoscopy
- ✓ Get peace of mind, sooner



Convenient testing

ColoSTAT[®] is highly effective test if you're showing symptoms of colorectal cancer, such as:

- ✓ blood in your stool
- ✓ a change in your toilet habits
- ✓ unexplained tiredness or weight loss
- ✓ stomach pain

This blood test is very sensitive (91%), which is comparable to the current faecal-based tests (FIT). A negative result means that there is a less than 1% chance of colon cancer, helping to avoid unnecessary colonoscopies.

ColoSTAT[®] is a triage tool to help your doctor decide whether you need a colonoscopy.

It may be undertaken as part of your regular blood tests, making it a more convenient option than a stool test.

Perfect for low risk patients

- ✓ aged 45-84
- ✓ with symptoms of bowel cancer
- ✓ reluctant to do stool-based tests

Ask your doctor about ColoSTAT[®] and whether it's right for you.

Early detection key to recovery

Early detection is key to improving the survival of colorectal cancer.

In fact, if colorectal cancer is detected early and localised to the bowel, 5-year survival rates can be as high as 90%.



Late diagnosis, after the cancer has spread beyond the bowel, results in a 5-year survival of 13-15%.²

ColoSTAT[®] may help speed up the diagnosis, getting you the treatment you need as quickly as possible.

Prevents unnecessary procedures

Each year in Australia, about 14,000 to 15,000 cancers are diagnosed from about 800,000 colonoscopies on symptomatic patients. This is roughly 1.8%.³



ColoSTAT has a sensitivity of 91% including for early-stage cancers. That means that 9 out of 10 cancers are detected.⁴

By improving the way patients with symptoms are referred for colonoscopy, it may free up space for those who truly need the procedure, reducing your wait time and speeding up the time to diagnosis.